Market Intelligence, Clinical Progress, and High-Purity Reagents for Lipid Antigen Presentation and Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CD1e drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD1e ECD-Fc Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). Suitable for lipid-binding assays. |
View CD1E Products |
| Gene Delivery | CD1e Promise-ORF / Lentivirus Full-length ORF for stable cell line construction. Essential for studying intracellular trafficking and lysosomal processing. |
View CD1E Products |
| Benchmark Ab | Anti-CD1e Recombinant Antibody Recombinant positive control for flow cytometry and immunohistochemistry (IHC). |
View CD1E Products |
| Validator | CD1e siRNA Set For knockdown verification in dendritic cell models. |
View CD1E Products |
| Related Target A | CD1b CD1e acts as an intracellular lipid chaperone that directly facilitates lipid loading onto CD1b. Co-evaluation is critical. |
View CD1B Products |
| Related Target B | CD1d Involved in glycolipid presentation to NKT cells; used for family-wide specificity and selectivity profiling. |
View CD1D Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intracellular Cleavage & Solubilization Mimicry | Truncated CD1e recombinant proteins designed to match the endogenous lysosomal cleaved active form (Theoretical MW verified). |
| Lipid-Binding Interference (Endotoxin/Lipid Contamination) | Ultra-low endotoxin levels (<1.0 EU/μg) and strict lipid-free purification protocols to ensure unoccupied lipid-binding grooves. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies and recombinant positive controls included. |
| False Positives in Cellular Assays | Sequence-specific validated siRNA included for target-specific knockdown verification. |
Live CD1e R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CD1e therapeutics is intensifying, with major players shifting focus from traditional mAbs to modulators of lipid antigen presentation. As first-generation immunotherapies reach the clinic, the next wave of R&D is targeting the intracellular lipid-chaperone function of CD1e, particularly in the context of mycobacterial infections (such as Tuberculosis) and autoimmune lipid hypersensitivity. Because CD1e uniquely localizes to endosomes and lysosomes to assist other CD1 members (like CD1b) in presenting hydrophobic antigens, therapeutic strategies are moving toward small molecule inhibitors of CD1e-lipid binding or bispecific constructs targeting the CD1e-lipid-CD1b presentation complex.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Institutes, Biotech Startups | Tuberculosis, Autoimmune Diseases | Lipid-binding displacement assays (Need high-purity, unoccupied lipid-groove CD1e recombinant proteins) |
| Monoclonal Antibodies | Biopharma Innovators | Cutaneous T-cell Lymphoma, Inflammatory Disorders | Intracellular internalization and IHC validation (Need HEK293-expressed CD1e and Lentivirus for cell lines) |
| Lipid-based Vaccines | Infectious Disease Consortia | Mycobacterium tuberculosis Immunization | In vitro lipid transfer assays (Need CD1e-mediated lipid loading onto CD1b recombinant heterodimers) |